Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
James Cannon
Period: Reporting period mapped to calendar 2024 Q4.
- Questions
- 2on tracked calls
- Challenge rate
- 0%none of 2 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 1with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 2 of 2 questions from 2 companies
ECLEcolab1 question · 1 reporting period · 0 of 1 challenging
Calendar 2024 Q4
what the remaining standalone life sciences business looks like
Show response
Beck quantified healthcare at ~$500M moving to INS with ~1pp top-line and margin impact. Life sciences $500M-$1B with underlying mid-twenties OI.
GLWCorning Inc.1 question · 1 reporting period · 0 of 1 challenging
Calendar 2024 Q4
I just wanted to see if you've had any orders start to come in under that? Or if it's still pointing towards kind of that 2026 timeline?
Show response
Weeks confirmed earliest trickles of BEAD orders that support the TAM view, but too little data to draw conclusions. No material revenue impact expected before 2026.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| ECL Ecolab | 1 | —Rate withheld: fewer than 3 questions |
| GLW Corning Inc. | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 2 | 0%none of 2 questions | 2 |
- 2024 Q42 questions · challenge rate 0% (none of 2 questions) · 2 companies
Topics
Topics tagged on this analyst’s questions.
- Margin1
- Revenue Growth1
- Regulation Policy1
- Demand1